Back to Authors

Li, Jiang

0000-0002-9791-2553

Mayo Clinic

Mayo Clinic

Citations 3

Vasopressin V1a and V1b receptor antagonism does not affect the efficacy of tolvaptan in polycystic kidney disease
Nanayakkara, K.D.L. , Hu, Jinghua , Nanayakkara, Kavini , Hu, Jinghua , Torres, Vicente E , Wang, Xiaofang , Li, Jiang , Torres, Vicente E.

American Journal of Physiology-Renal Physiology | May 26, 2025 | Volume: 329 | Issue: 1 | Pages: F20-F31

10.1152/ajprenal.00350.2024 Get It

Currently, the vasopressin V2 receptor antagonist tolvaptan is the only approved treatment for autosomal dominant polycystic kidney disease (ADPKD). It has been suggested that vasopressin acting on V1a or V1b receptors may also affect its development. We show that a V1aR antagonist has no effect in an ADPKD mouse model (Pkd1RC/RC), whereas a V2R antagonist has a modest attenuating effect in female mice only. Neither potentiates or hinders the beneficial effect of tolvaptan when administered in combination with this drug.
Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
Thao, Ka, LaBranche, Timothy P. , Palmer, Michael R., McKnight, Stanley, Hoeflich, Klaus P. , Schalm, Stefanie S. , Wang, Xiaofang , Li, Jiang , Sussman, Caroline R. , Palmer, Michael R., Harris, Peter C. , Torres, Vicente E.

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 393-393

10.1681/asn.20213210s1393b Get It

Fibromyalgia Symptom Severity and Psychosocial Outcomes in Fibromyalgia Patients with Hypovitaminosis D: A Prospective Questionnaire Study
D’Souza, Ryan S. , Oh, Terry H., Vincent, Ann , Orhurhu, Vwaire , Mauck, William D. , Qu, Wenchun , Lin, Ge, Oh, Terry, D'Souza, Ryan S , Lin, Ge, Li, Jiang

Pain Medicine | December 19, 2019 | Volume: 21 | Issue: 12 | Pages: 3470-3478

10.1093/pm/pnz377 Get It

Abstract Objective To evaluate the association between hypovitaminosis D and outcomes of symptom severity, mood disorders, fatigue, and quality of life in fibromyalgia (FM) patients. Methods Five hundred ninety-three FM patients were surveyed from May 2012 to November 2013. Patients with serum vitamin D <25 ng/mL were considered to have hypovitaminosis D. The primary outcome was FM symptom severity (FIQ-R questionnaire). Secondary outcomes included quality of life (SF-36), fatigue (MFI-20), anxiety (GAD-7), and depression (PHQ-9). Independent t tests and chi-square tests were performed for continuous and categorical variables, respectively. Regression analysis was performed adjusting for age, gender, body mass index, ethnicity, and season. A post hoc analysis examined for correlation between outcomes and serum vitamin D (ng/mL) as a continuous variable. Results One hundred twenty-two patients (20.6%) had hypovitaminosis D. In our adjusted regression analysis, the total FIQ-R score in patients with hypovitaminosis D was higher compared with control patients with adequate serum vitamin D (57.85 ± 18.09 vs 62.79 ± 18.10, P = 0.04). Adjusted regression analysis revealed higher total GAD-7 (P = 0.01) and higher total PHQ-9 scores (P = 0.04) in patients with hypovitaminosis D compared with control patients. There were no differences based on severity of depression or anxiety. No differences in fatigue or quality of life were identified. Unadjusted post hoc analysis revealed that as serum vitamin D increased, there was an association with lower total FIQ-R (β coefficient = –0.11, P = 0.02) and lower SF-36 subscale scores of role-physical (β coefficient = –0.10, P = 0.03). Adjusted post hoc analysis revealed no significant associations. Conclusions Hypovitaminosis D may be a risk factor for worse symptom severity, anxiety, and depression in FM patients.